Skip to main content

Other

Retrospective study of 201 IPAF (Interstitial pneumonia w/ autoimmune feat.) pts w/ F/U 5.6 yrs. ANA+ 80%, RF+ 25%, CCP+ 14%, 88% Rx w/ IS or antifibrotics. 24% died, 7.5% transplant. Comorbidies were common; mean CCI 3.2; IPAF mortality worsened by

Dr. John Cush @RheumNow( View Tweet )

🆕 ILD (Part II): advanced insights 🫁 Multidisciplinary management 💊 Treatment strategies 📊 Prognosis & monitoring 🧑⚕️ What rheums should know next ⬇️ Download & learn more: https://t.co/dmhULfqiMj Created by @MithuRheum | For our Rheum to Breathe: ILD Campaign https://t.co/ivvDjxkCvt
Dr. John Cush @RheumNow( View Tweet )
Non-Pharmacologic ILD Care Jon T. Giles, MD, MPH, discusses non-Pharmacologic approaches to ILD treatment and patient care. Sponsored By: Boehringer Ingelheim https://t.co/Mxg9P50m7C #ILD #Rheumatology https://t.co/5wD1K7J1Gq
Dr. John Cush @RheumNow( View Tweet )

SARD-ILD: Significant diagnostic and treatment delays

Should we be screening all our patients with systemic autoimmune rheumatic disease (SARD) for interstitial lung disease? I have been asking myself that question after the recent publication of American Thoracic Society Interstitial Lung Disease screening guidelines. The ATS guidelines, which

Read Article
QD Clinic: Beyond the Numbers in Newly Diagnosed ILD Dr. Eric Dein, Summit, NJ, presents a case of a new patient with interstitial lung disease, as part of RheumNow's Rheum to Breathe: ILD campaign, presented throughout the month of September 2025. https://t.co/HLnX5WbbTw https://t.co/SZeI4bqSAm
Dr. John Cush @RheumNow( View Tweet )
How to assess ILD in your patients? Have a high index of suspicion in your patients with connective tissue disease (especially systemic sclerosis, inflammatory myositis), and rheumatoid arthritis. All patients with CTD may develop ILD but it is more common (% of patients with https://t.co/UXdvPJCqDi
Dr. John Cush @RheumNow( View Tweet )
Nitazenes — a class of highly potent synthetic opioids — are rapidly emerging as a major contributor to the overdose crisis; they are over 20 times more potent than fentanyl. Nitazenes are an illegal Schedule I drug that are rapidly spreading in the illicit drug market

Dr. John Cush @RheumNow( View Tweet )

RheumNow Podcast – Ro, Ro, Ro52 (9.12.2025) Dr. Jack Cush reviews the news and journal reports from the past week on RheumNow.Are there benefits to diet or vegan diets? What's the effect of menopause on CTD? Ro52 makes a big entrance with all our ILD coverage this month. https://t.co/T68Cprogm3
Dr. John Cush @RheumNow( View Tweet )
Definitions for Interstitial Lung Disease: A Consensusfrom the Fleischner Society https://t.co/gEqmkdJLDh https://t.co/8nnWKbKjk9
Dr. John Cush @RheumNow( View Tweet )
Call to Update the Classification Criteria in Idiopathic Inflammatory Myopathies (IMM), Why? - EULAR/ACR myositis criteria dont cover specific myositis subtypes - Polymyositis is rare - antisynthetase & necrotizing myopathy & Jo1 Dz not well represented - Need to include MSA, https://t.co/LUfF0VCeJ7
Dr. John Cush @RheumNow( View Tweet )
My article 👇 summarizing the 2025 update of EULAR recommendations by @eular_org, presented by Josef Smolen at @APLAR_org https://t.co/QFWZmqm6IR @RheumNow #APLAR25 https://t.co/ctQdu8gQEO

Aurelie Najm @AurelieRheumo( View Tweet )

A self learning program to train non Rheumatologists to interpret pelvic X-rays and identify sacro-iliitis? It works, but it seems the participants were already well trained as pre test scores were already reaching 60+% Surprised to see radiologists constituting 1/4 of the test https://t.co/mRcFRSuAws
Aurelie Najm @AurelieRheumo( View Tweet )
PsO/PsA patients have an ⬆️ CV risk brought about by traditional and CV risk factors. Do you perform regular CV risk screening in your patients? @RheumNow #APLAR25 https://t.co/BGNKrKeLsI

SARD-ILD and serious infection risk: The elephant in the room

Interstitial lung disease (ILD) remains one of the largest unmet clinical needs across many systemic autoimmune rheumatic diseases (SARD). Clinicians are already keenly aware of the complexity of patients with SARD-ILD. The “elephant in the room” for all these issues: serious infection.

Read Article
Hospital for Special Surgery (HSS) reports that ear acupuncture applied during hip replacement surgery reduces pain and lessens opioid use over the weeks to follow. https://t.co/lOrwb1DzW5 https://t.co/6rkHNTwaAl
Dr. John Cush @RheumNow( View Tweet )
RCT of 800 adults w/ Chronic LBP, acupuncture (AP) was compared usual care or AP +/- added maintenance found that acupuncture improved pain-related disability at 6 months and 12 months, with no statistically discernible benefit of additional maintenance sessions. https://t.co/suy09fGxxI
Dr. John Cush @RheumNow( View Tweet )
SLE and Osteoporosis Systemic Lupus Erythematosus (SLE) is a multisystem autoimmune disease that can present with a variety of signs and symptoms and organ involvement. Comorbidities further complicate the disease course that may lead to poor health-related quality of life and https://t.co/8ZmtLjzbqA
Dr. John Cush @RheumNow( View Tweet )

When Myositis Hits the Lungs: What Every Rheumatologist Should Know About ILD

When idiopathic inflammatory myopathies (IIM) affect the lungs, the consequences can be serious. ILD is not only common in IIM, but also one of the leading causes of death, contributing to up to 80% of mortality in this patient group. For rheumatologists, two subsets stand out: anti-synthetase

Read Article
PAH, when associated with ILD in CTD, worsens prognosis, and poses challenges for treatment Summary of when PAH should be assessed in patients with ILD and when to perform a right heart catheterization by Prof Kuwana @RheumNow #APLAR25 https://t.co/g4x4ENzc9k
Aurelie Najm @AurelieRheumo( View Tweet )
How to treat CTD ILD? A comparative slide summarizing ACR/BSR and EULAR treatment guidelines Emphasis on combination of Immunosuppressant and Antifibrotics @RheumNow #APLAR25 https://t.co/gLSht6QKh5
Aurelie Najm @AurelieRheumo( View Tweet )
A framework for treatment stratified approach in CTD-ILD, by Dr Low Hsiu Ling Based on -ILD extent -Risk of progression -Biology: fibrosis/inflammation -Safety -Other manifestations @RheumNow #APLAR25 https://t.co/ma5KugzBHy
Aurelie Najm @AurelieRheumo( View Tweet )
Why shall we screen all patients with SSc for ILD? Focusing screening strategy on patients « at risk » misses 25% of patients with ILD ILD being the main cause of mortality in SSc @RheumNow #APLAR25 https://t.co/djzCTdZoVb
Aurelie Najm @AurelieRheumo( View Tweet )
An important message from Prof. @XBaraliakos on D2M-axSpA: Re-evaluate your diagnosis & check for comorbids before labelling pts as tx-refractory or difficult-to-manage. consider other causes: FM, other causes of pain @RheumNow #APLAR25 @rheumarhyme @marklagacmd https://t.co/Lo0yShOK0P
Hyperferritinemia is common in Hyperinflammatory syndromes but is a hallmark of Macrophage activation syndrome and Sepsis; and is a poor prognostic sign too. MAS is excessive activation of T-lymphocytes & macrophages leading to cytokine storm & multi-organ damage. https://t.co/MUKXC0Tw3M
Dr. John Cush @RheumNow( View Tweet )
🆕 Intro to ILD (Part I): the essentials 🫁 Definition & basics 🔬 Key pathology patterns 🧑⚕️ Clinical approach 📋 What rheums need to know ⬇️ Download & learn more: https://t.co/7RzpTDOjwa Created by @MithuRheum | via @RheumNow for our Rheum to Breathe: ILD Campaign https://t.co/D9d97bqcD5
Dr. John Cush @RheumNow( View Tweet )
×